You have a patient with a warm autoantibody.
The antibody screen is positive.
The panel is positive.
The autocontrol is positive.
The DAT is positive.
And now every unit you crossmatch is incompatible.
The physician still wants blood.
Welp. They'll have to sign a form to agree to transfuse "Least Incompatible" Blood. That will go over well.. I can't tell you how many times I had to refer off to the resident/fellow so they can go head to head over what this meant...Sounds reassuring, right?
In fact, the phrase “least incompatible” has been criticized in transfusion medicine for decades because it can be misleading and provides very little useful information about the actual safety of a transfusion. Lawrence Petz argued in Transfusion in 2003 that the term should essentially be abandoned because selecting units based on weaker crossmatch reactions does not establish that those cells will survive better in the patient.
So why do we still hear it?
Why Is Everything Incompatible?
The classic situation involves a warm-reactive autoantibody.
Unlike an alloantibody, which recognizes an antigen the patient lacks, an autoantibody reacts against an antigen present on the patient's own red blood cells.
Many warm autoantibodies demonstrate broad specificity.
That means the antibody may react with:
the patient's RBCs
and
most or all donor RBCs
and
all of your screening and panel cells.
So when you perform an AHG crossmatch with donor units, you may get:
Unit 1: 2+ incompatible
Unit 2: 1+ incompatible
Unit 3: 2+ incompatible
Unit 4: 1+ incompatible
None of them are actually serologically compatible.
Historically, some laboratories would crossmatch several units and choose the unit showing the weakest reaction.
That became the:
“least incompatible” unit.
But Is a 1+ Unit Actually Safer Than a 2+ Unit?
Not necessarily.
And that's the problem.
The strength of the serologic reaction between a patient's warm autoantibody and a donor unit does not reliably predict how well that particular donor unit will survive after transfusion. The old practice of selecting the weakest-reacting unit therefore gives the appearance of increased safety without demonstrating that the chosen unit is biologically superior.
The autoantibody is already attacking the patient's own RBCs.
Once donor RBCs enter the circulation, they may also be exposed to that autoantibody.
In many cases, the transfused cells can still provide useful oxygen-carrying capacity even though their survival may be shortened. Broadly reactive warm autoantibodies can cause essentially all donor RBCs to appear incompatible during testing, yet transfusion can still provide clinical benefit when it is needed.
So the important question isn't:
“Which unit reacts 1+ instead of 2+?”
The important question is:
“Is there a clinically significant ALLOantibody hiding underneath this autoantibody?”
That's the Real Blood Bank Problem
Imagine a patient has a warm autoantibody that reacts with everything.
Fine.
But buried underneath that autoantibody, the patient also has:
anti-E.
Now things are very different.
The warm autoantibody may make both E-positive and E-negative donor cells incompatible in the crossmatch.
But the E-positive unit carries an additional, avoidable risk because the patient has a clinically significant alloantibody against E.
Simply lining up units and choosing the one with the weakest crossmatch reaction may completely fail to detect that problem.
That's why investigations involving warm autoantibodies focus heavily on determining whether underlying alloantibodies are present. AABB educational material specifically emphasizes evaluating the plasma for underlying alloantibodies before transfusion in this setting, using adsorption techniques when appropriate.
Enter Adsorption
The basic concept is:
Get the autoantibody out of the plasma so you can see what else is hiding underneath it.
There are two major approaches.
Autoadsorption
If circumstances allow, the patient's own RBCs can be used to adsorb the autoantibody from their plasma.
The patient's plasma is incubated with treated patient RBCs.
The autoantibody binds to those cells.
The adsorbed plasma is removed.
Repeat as necessary.
Eventually, much of the interfering autoantibody can be removed.
Now test the adsorbed plasma against reagent cells again.
If everything becomes negative?
Great. That supports the idea that the broad reactivity was caused by the autoantibody and that no detectable underlying alloantibody remains.
If specific reactions remain?
Now you may be uncovering an alloantibody that had previously been hidden by the panreactive autoantibody. AABB's case-based material uses warm adsorption specifically for this purpose.
Alloadsorption
Sometimes you can't safely use the patient's own RBCs.
A major example is the recently transfused patient.
If donor RBCs are circulating in the patient's sample, you may not actually know which cells belong to the patient anymore.
Selected donor RBCs can instead be used in a series of allogeneic adsorptions designed to remove the autoantibody while preserving the ability to detect clinically significant alloantibodies.
This can get complicated very quickly.
Which, naturally, is when everybody starts calling the reference lab.
Phenotype and Genotype Help Too
Another major part of the investigation is figuring out what antigens the patient actually possesses.
If the patient is:
E-negative
K-negative
Jk(a−)
Fy(a+)
then antibodies such as anti-E, anti-K, and anti-Jkᵃ are biologically possible, while conventional alloanti-Fyᵃ would not normally make sense.
An extended phenotype can therefore help narrow the antibody investigation and guide selection of donor units.
Recent transfusion or heavy RBC coating can make serologic phenotyping difficult, which is one reason molecular red-cell genotyping can be so useful in complicated autoimmune hemolytic anemia cases.
The end goal is not to find a donor unit that produces the prettiest-looking crossmatch.
The goal is to provide RBCs that lack antigens corresponding to any clinically significant alloantibodies and, when appropriate, provide additional antigen matching based on the patient's phenotype or genotype.
So What If the Autoantibody Still Makes the Crossmatch Positive?
It probably will.
That's the important psychological hurdle.
Imagine you've completed the investigation and determined:
Patient is group A positive
Warm autoantibody is present
DAT is positive with IgG
Adsorbed plasma shows no detectable clinically significant alloantibodies
Historical antibody review is negative
Appropriate donor units have been selected
You crossmatch them using the patient's original plasma.
Still incompatible.
Of course they are.
The autoantibody is still in the patient's plasma.
That doesn't suddenly mean you discovered a new transfusion incompatibility.
It means the serologic incompatibility you already knew about is still detectable.
This is why communicating simply:
“We're giving least incompatible blood.”
can actually make things worse.
The clinician may hear:
“We couldn't find compatible blood, but we found the unit that is least likely to kill them.”
What the Blood Bank may actually mean is:
“The patient's warm autoantibody reacts with donor RBCs, but our investigation has not demonstrated an underlying clinically significant alloantibody, and we have selected appropriately matched units.”
Those are very different messages.
“Least Incompatible” Doesn't Mean “Unsafe”
Another problem with the phrase is that clinicians may become afraid to transfuse a patient who genuinely needs RBCs.
If every crossmatch says INCOMPATIBLE, it can look terrifying.
But severe anemia itself is dangerous.
Transfusion in AIHA should be based on the patient's clinical condition rather than withheld simply because a warm autoantibody makes the serologic crossmatch incompatible. Published transfusion literature has repeatedly emphasized that necessary transfusion should not be delayed merely in pursuit of a cosmetically compatible crossmatch when appropriate investigation has excluded clinically important alloantibodies.
This becomes especially important when the patient is:
profoundly anemic
symptomatic
actively bleeding
hemodynamically unstable
experiencing ischemia
or otherwise unable to wait hours for a complete reference-laboratory investigation
The Blood Bank and physician then have to balance the risks of transfusion against the much more immediate risk of not transfusing.
But Studies Say “Least Incompatible” Blood Can Be Safe!
You may still encounter studies describing transfusion of “least incompatible” RBCs in AIHA.
And several have found that patients transfused with these units achieve expected hemoglobin increases without evidence of dramatically increased hemolysis. More recent observational work has reached similar conclusions.
That doesn't really vindicate the terminology.
It demonstrates something slightly different:
Patients with warm autoantibodies can often be safely transfused despite serologic incompatibility when clinically significant alloantibodies have been appropriately addressed.
It does not prove that selecting the 1+ crossmatch instead of the 2+ crossmatch is what made the transfusion safer.
That's the distinction.
So What Should We Call It?
There isn't one magical replacement phrase, because the useful communication depends on what testing has actually been performed.
Something like:
“Serologically incompatible due to warm autoantibody; no underlying alloantibodies detected.”
is far more informative.
Or:
“Phenotype-matched RBCs selected; crossmatch remains incompatible secondary to warm autoantibody.”
If an alloantibody exists:
“E-negative, K-negative RBCs selected; residual incompatibility is attributable to the patient's warm autoantibody.”
Now the physician knows:
Why the crossmatch is incompatible.
What the Blood Bank did about it.
Whether clinically significant alloantibodies have been identified.
Why transfusion is still considered reasonable.
That's considerably more useful than:
“Don't worry. We found the least bad one.”
When “Incompatible” Really DOES Matter
None of this means incompatible crossmatches should simply be ignored.
Quite the opposite.
An incompatible crossmatch caused by an alloantibody against a donor antigen is fundamentally different from residual incompatibility caused by a known broad warm autoantibody.
If the patient has anti-Jkᵃ and you give Jk(a+) RBCs because they happened to react slightly less strongly than another unit:
That's not clever.
That's giving antigen-positive blood to a patient with a clinically significant antibody.
The entire point of the autoimmune investigation is therefore to determine whether the incompatibility represents:
expected autoantibody reactivity
or
an avoidable alloimmune incompatibility.
And that's exactly why simply grading crossmatches and picking the weakest one is inadequate.
The Takeaway
“Least incompatible” sounds like a meaningful measure of transfusion safety.
Usually, it isn't.
In a patient with a broadly reactive warm autoantibody, every donor unit may appear incompatible because the autoantibody reacts with essentially everyone else's red cells just as it reacts with the patient's own.
Testing five units and selecting whichever one reacts weakest doesn't prove that unit will survive longer or be safer after transfusion. That criticism of the term has been made in the transfusion-medicine literature for decades.
The real Blood Bank work is:
Identify the autoantibody.
Look for underlying clinically significant alloantibodies.
Honor historical antibodies.
Use phenotype or genotype information when appropriate.
Select antigen-negative or appropriately matched RBCs.
Communicate why residual serologic incompatibility remains.
Sometimes there simply isn't a crossmatch-compatible unit.
And sometimes that's okay.
Because the goal isn't to make the crossmatch screen look pretty.
The goal is to make sure the incompatibility you're seeing is the one you already understand—and not another clinically significant antibody hiding underneath it.